<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Microbiol</journal-id><journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Microbiology</journal-title></journal-title-group><issn pub-type="epub">1664-302X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6803450</article-id><article-id pub-id-type="doi">10.3389/fmicb.2019.02367</article-id><article-categories><subj-group subj-group-type="heading"><subject>Microbiology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Hampering Herpesviruses HHV-1 and HHV-2 Infection by Extract of <italic>Ginkgo biloba</italic> (EGb) and Its Phytochemical Constituents</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sochocka</surname><given-names>Marta</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/752721/overview"/></contrib><contrib contrib-type="author"><name><surname>Sobczy&#x00144;ski</surname><given-names>Maciej</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ochnik</surname><given-names>Micha&#x00142;</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zwoli&#x00144;ska</surname><given-names>Katarzyna</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Leszek</surname><given-names>Jerzy</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/491961/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Laboratory of Virology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences</institution>, <addr-line>Wroc&#x00142;aw</addr-line>, <country>Poland</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Genomics, Faculty of Biotechnology, University of Wroc&#x00142;aw</institution>, <addr-line>Wroc&#x00142;aw</addr-line>, <country>Poland</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Psychiatry, Wroc&#x00142;aw Medical University</institution>, <addr-line>Wroc&#x00142;aw</addr-line>, <country>Poland</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Anthony Nicola, Washington State University, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Konstantin Kousoulas, Louisiana State University, United States; Oren Kobiler, Tel Aviv University, Israel</p></fn><corresp id="c001">*Correspondence: Marta Sochocka, <email>marta.sochocka@hirszfeld.pl</email></corresp><fn fn-type="other" id="fn004"><p>This article was submitted to Virology, a section of the journal Frontiers in Microbiology</p></fn></author-notes><pub-date pub-type="epub"><day>15</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>10</volume><elocation-id>2367</elocation-id><history><date date-type="received"><day>17</day><month>6</month><year>2019</year></date><date date-type="accepted"><day>30</day><month>9</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2019 Sochocka, Sobczy&#x00144;ski, Ochnik, Zwoli&#x00144;ska and Leszek.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Sochocka, Sobczy&#x00144;ski, Ochnik, Zwoli&#x00144;ska and Leszek</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Despite the availability of several anti-herpesviral agents, it should be emphasized that the need for new inhibitors is highly encouraged due to the increasing resistant viral strains as well as complications linked with periods of recurring viral replication and reactivation of latent herpes infection. Extract of <italic>Ginkgo biloba</italic> (EGb) is a common phytotherapeutics around the world with health benefits. Limited studies, however, have addressed the potential antiviral activities of EGb, including herpesviruses such as <italic>Human alphaherpesvirus 1</italic> (HHV-1) and <italic>Human alphaherpesvirus 2</italic> (HHV-2). We evaluated the antiviral activity of EGb and its phytochemical constituents: flavonoids and terpenes against HHV-1 and HHV-2. Pretreatment of the herpesviruses with EGb prior to infection of cells produced a remarkable anti-HHV-1 and anti-HHV-2 activity. The extract affected the viruses before adsorption to cell surface at non-cytotoxic concentrations. In this work, through a comprehensive anti-HHV-1 and anti-HHV-2 activity study, it was revealed that flavonoids, especially isorhamnetin, are responsible for the antiviral activity of EGb. Such activity was absent in quercetin and kaempferol. However, EGb showed the most potent antiviral potency compared to isorhamnetin. EGb could augment current therapies for herpes labialis and genital herpes. Moreover, the potential use of EGb in multidrug therapy with synthetic anti-herpes compounds might be considered.</p></abstract><kwd-group><kwd>extract of <italic>Ginkgo biloba</italic> (EGb)</kwd><kwd>isorhamnetin</kwd><kwd>HHV-1</kwd><kwd>HHV-2</kwd><kwd>antiviral activity</kwd><kwd>viral particles trapping</kwd></kwd-group><counts><fig-count count="4"/><table-count count="2"/><equation-count count="0"/><ref-count count="32"/><page-count count="11"/><word-count count="0"/></counts></article-meta></front><body><sec id="S1"><title>Introduction</title><p>Viral infections are still a key public health problem and a significant cause of many epidemic diseases worldwide. Vaccines and antiviral therapies are effective tools to control viral infections. There are many vaccines for viral diseases like measles, flu, or rubella. On the other hand, antiviral drugs play an important role against viral pathogens for which protective vaccines are unavailable, such as <italic>Human alphaherpesvirus 1</italic> (HHV-1) (<xref rid="B4" ref-type="bibr">Birkmann and Zimmermann, 2016</xref>). HHV-1 and <italic>Human alphaherpesvirus 2</italic> (HHV-2) belong to the most common worldwide infections of humans, producing lifelong infection. It is estimated that among people under the age of 50, 3.7 billion are infected with HHV-1 and about 417 million suffer of HHV-2 infection (<xref rid="B23" ref-type="bibr">Rechenchoski et al., 2017</xref>). After primary infection, through the mucous membrane or damaged skin, viruses become latent and exist in the trigeminal ganglia (HHV-1) or lumbar-sacral ganglia (HHV-2) (<xref rid="B5" ref-type="bibr">Boldogh et al., 1996</xref>). Several factors, such as UV, stress, injury, immune impairment, or immunosenescence lead to virus reactivation in the place of the initial infection, causing pain, and skin ailments (blisters filled with serous fluid with active virions). Skin lesions are related the oral cavity, lips, hands, or genital organs (<xref rid="B23" ref-type="bibr">Rechenchoski et al., 2017</xref>). In extreme situations, reactivation of HHV-1 can lead to serious complications such as encephalitis and meningitis (<xref rid="B27" ref-type="bibr">Tyler, 2004</xref>). It was shown that HHV-1 can enter the brain in older age and establish a latent infection (<xref rid="B11" ref-type="bibr">Itzhaki, 2018</xref>). Recurrent reactivation, in turn, causes the activation of neuroinflammatory process and herpes simplex encephalitis (HSE). It is suggested that incidents of mild HSE may lead to Alzheimer&#x02019;s disease (AD) (<xref rid="B12" ref-type="bibr">Itzhaki and Tabet, 2017</xref>). Several antivirals are available for HHV-1 and HHV-2 infections, such as acyclovir, valacyclovir cydofovir, or penciclovir (<xref rid="B13" ref-type="bibr">James and Prichard, 2014</xref>). These preparations, however, have shortcomings such as a relatively fast emergence of resistance in the immunocompromised patients and risk of generating drug-resistant infections. Moreover, drug toxic side effects were also reported (<xref rid="B13" ref-type="bibr">James and Prichard, 2014</xref>). Therefore, it is necessary to develop and expand the scope of antivirals. We believe that the most promising are preparations of a natural origin as an alternative to commercially available synthetic preparations.</p><p>Plants are a valuable source of substances with antiviral activities as a defense against invading pathogens. Extract of <italic>Ginkgo biloba</italic> (EGb) dried green leaves belongs to the most common phytotherapeutics around the world (<xref rid="B10" ref-type="bibr">Isah, 2015</xref>). EGb has a long history of use in the treatment of heart and lung diseases, and is also known to improve memory function (<xref rid="B20" ref-type="bibr">Mohanta et al., 2014</xref>). EGb is commercially available as a one of the five top-selling herbal supplements (<xref rid="B28" ref-type="bibr">Ude et al., 2013</xref>). Flavonoids, terpenes, and organic acids are the main components of EGb. The standardized extract contains flavonoids expressed as flavone glycosides (22&#x02013;27%), e.g., kaempferol, quercetin, isorhamnetin, 2.8&#x02013;3.4% terpene trilactones (ginkgolides A, B, C), 2.6&#x02013;3.2% bilobalide and less than 5 ppm ginkgolic acids due to its cytotoxic potency (<xref rid="B20" ref-type="bibr">Mohanta et al., 2014</xref>; <xref rid="B10" ref-type="bibr">Isah, 2015</xref>). The scientifically proven effect of EGb is related to the beneficial influence on the CNS and cardiovascular systems. It is widely used in various neurodegenerative diseases such as Parkinson&#x02019;s Disease or AD (<xref rid="B32" ref-type="bibr">Zuo et al., 2017</xref>). In the abundant scientific data indicating the therapeutic properties of EGb, there is no information about the use of EGb in the prevention and treatment of viral diseases. Limited scientific information indicated the potential antiviral activities of EGb or <italic>G. biloba</italic> compounds for several viruses. It was showed that polysaccharides from <italic>G. biloba</italic> fruit exocarp exhibit activity against PEDV (<italic>Porcine epidemic diarrhea virus</italic>) (<xref rid="B17" ref-type="bibr">Lee et al., 2015</xref>), and ginkgolic acid from <italic>G. biloba</italic> inhibited HIV (<italic>Human immunodeficiency virus</italic>) protease (<xref rid="B18" ref-type="bibr">L&#x000fc; et al., 2012</xref>). Nanoemulsion with polyphenols isolated from <italic>G. biloba</italic> leaves and EGb exhibit anti-influenza H1N1 and H3N2 activity as well as anti-HBV (<italic>Hepatitis B virus</italic>) (<xref rid="B8" ref-type="bibr">Haruyama and Nagata, 2013</xref>; <xref rid="B29" ref-type="bibr">Wang et al., 2015</xref>).</p><p>In the present <italic>in vitro</italic> studies, we investigated the antiviral activity of standardized EGb against HHV-1 and HHV-2. In addition, we have analyzed the effectiveness of EGb and isorhamnetin in diminishing HHV-1 and HHV-2 infectivity.</p></sec><sec sec-type="materials|methods" id="S2"><title>Materials and Methods</title><sec id="S2.SS1"><title>Viruses and Cell Line</title><p><italic>Human alphaherpesvirus 1</italic>; MacIntyre strain, <italic>Herpesviridae</italic> (HHV-1, ATTC VR-539); <italic>Human alphaherpesvirus 2</italic>; MS strain, <italic>Herpesviridae</italic> (HHV-2, ATTC VR-540). HHV-1 and HHV-2 were grown and titrated in A549 cells. The titer was expressed with reference to the TCID<sub>50</sub> (tissue culture infectious dose) value, based on the cytopathic effects (CPEs) caused by this virus in approximately 50% of infected cells.</p><p>A549 (ATCC CCL 185), a human epithelial-like cell line, was maintained in Dulbecco&#x02019;s Modified Eagle Medium (DMEM) (HIIET PAS, Wroc&#x00142;aw, Poland) with antibiotics (100 U/mL penicillin and 100 &#x003bc;g/mL streptomycin), 2 m<sc>M L</sc>-glutamine, and 10% fetal bovine serum (FBS) (all from Sigma-Aldrich, United States).</p></sec><sec id="S2.SS2"><title>Extract of <italic>G. biloba</italic> (EGb)</title><p>Standardized dry extract from <italic>G. biloba</italic> leaves (GINKGONIS EXTRACTUM SICCUM RAFFINATUM ET QUANTIFICATUM PH. EUR. [European Pharmacopoeia]) provided by Martin Bauer Group, Finzelberg GmbH &#x00026; Co. KG, Andernach, Germany was investigated. EGb is a dry extract from <italic>Ginkgo biloba</italic> leaves. The extract is adjusted to 22.0&#x02013;27.0% ginkgo flavonoids calculated as ginkgo flavone glycosides, and 5.0&#x02013;7.0% terpene lactones consisting of 2.8&#x02013;3.4% ginkgolides A, B, C and 2.6&#x02013;3.2% bilobalide, and contains less than 5 ppm ginkgolic acids. For a detailed description (HPLC results, microbiological examination) [see section &#x0201c;EGb Characterization&#x0201d; (<xref ref-type="supplementary-material" rid="SM1">Supplementary File-Table 1</xref>)].</p><sec id="S2.SS2.SSS1"><title>EGb Solution</title><p>Before each experiment, EGb was dissolved in dimethyl sulfoxide (DMSO) at a primary concentration of 20 mg/ml and mixed thoroughly until complete dissolution. Next, serial concentration of EGb (25&#x02013;1000 &#x003bc;g/ml) in DMEM 2% FBS was prepared for experiments.</p></sec></sec><sec id="S2.SS3"><title><italic>G. biloba</italic> Flavonoids Mix</title><p>A mix of flavonoids from <italic>G. biloba</italic>: kaempferol, quercetin, and isorhamnetin (100 &#x003bc;g/ml each component in methanol) was obtained from Sigma-Aldrich (St. Louis, MO, United States). Serial concentrations (6&#x02013;25 &#x003bc;g/ml) were prepared in DMEM 2% FBS for experiments. Methanol (25% and below) does not cause viral inactivation (control). Final concentrations of methanol in tested cells were &#x02264; 2.5% (non-toxic concentration, control).</p></sec><sec id="S2.SS4"><title><italic>G. biloba</italic> Terpene Lactones Mix</title><p>A mix of terpene lactones from <italic>G. biloba</italic>: bilobalide, ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J (100 &#x003bc;g/mL each component in acetonitrile) was obtained from Sigma-Aldrich. Serial concentrations (1.5&#x02013;9 &#x003bc;g/ml) were prepared in DMEM 2% FBS for experiments. Acetonitrile (9% and below) does not cause viral inactivation (control). Final concentrations of acetonitrile in tested cells were &#x02264; 0.9% (non-toxic concentration, control).</p></sec><sec id="S2.SS5"><title>Flavonoids</title><p>Isorhamnetin (3&#x02032;-methoxy-3,4&#x02032;,5,7-tetrahydroxyflavone, 3&#x02032;- methylquercetin) &#x02265; 95.0% (HPLC); Kaempferol (3,4&#x02032;,5,7- tetrahydroxyflavone, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) &#x02265; 97.0% (HPLC); Quercetin (2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4- one, 3,3&#x02032;,4&#x02032;,5,6-pentahydroxyflavone) &#x02265; 95% (HPLC); all obtained from Sigma-Aldrich. Before each experiment, the tested compounds were dissolved in DMSO at primary concentrations, respectively: 5, 25, and 10 mg/ml and mixed thoroughly until complete dissolution. Next, dilution to 1 mg/ml was maintained in methanol. Serial concentrations of each compound (6&#x02013;25 &#x003bc;g/ml) in DMEM 2% FBS were prepared for experiments. The final concentration of DMSO in tested cells was &#x0003c; 1%. Methanol (25% and below) does not cause viral inactivation (control). Final concentrations of methanol in tested cells were &#x02264; 2.5% (non-toxic concentration, control).</p></sec><sec id="S2.SS6"><title>Luminescent Cell Viability Assay</title><p>CellTiter-Glo<sup>&#x000ae;</sup> Luminescent Cell Viability Assay (Promega, Poland) was used to determine the number of viable cells. 24-h cultures of A549 cell line were treated with several concentrations of EGb (25&#x02013;1000 &#x003bc;g/ml) and incubated for 72 h at 37&#x000b0;C. Next CellTiter-Glo assay was performed as previously described (<xref rid="B7" ref-type="bibr">Cre&#x00163;u et al., 2017</xref>). Control were cells treated only with culture medium DMEM 2% FBS.</p></sec><sec id="S2.SS7"><title>CTEs Cell Viability Assay</title><p>24-h cultures of A549 cell line were treated with several concentrations of EGb (25&#x02013;1000 &#x003bc;g/ml) and incubated for 72 h at 37&#x000b0;C. Morphological changes of the cells (cytotoxic effects, CTE) were observed every day under inverted microscope and cell viability was calculated based on CTEs, where, 0 - lack of cytotoxic effects, 1- CTEs in 25% of cells, 2 - CTEs in 50% of cells, 3 - CTEs in 75% of cells, and 4 &#x02013; 100% of the cells affected with CTEs. Control were cells treated only with culture medium DMEM 2% FBS.</p></sec><sec id="S2.SS8"><title>Early Viral Entry Assay (Inactivation Assay)</title><p>Inhibition of HHV-1 and HHV-2 replication was examined by early viral entry assay (inactivation assay). Serial concentrations of EGb, <italic>G. biloba</italic> flavonoids mix, <italic>G. biloba</italic> terpene lactones mix, isorhamnetin, kaempferol or quercetin were incubated with HHV-1 or HHV-2 for 0,5 h (&#x02018;Short-Term&#x02019;), 1 and 2 h (&#x02018;Long-Term&#x02019;) at room temperature. Next viruses-tested compounds mixtures were diluted (logarithmic scale) and adsorbed to A549 cells at density 1.8 &#x000d7; 10<sup>5</sup> cells/ml in 96-well plates. Plates were incubated in 37&#x000b0;C/5% CO<sub>2.</sub> After 3 days of incubation viral CPEs were observed and evaluated under inverted microscope, where, 0 - lack of viral replication (lack of CPEs), 1- viral CPEs in 25% of cells, 2 - viral CPEs in 50% of cells, 3 - viral CPEs in 75% of cells, and 4 - 100% of the cells affected with CPEs. Viral titer was expressed with reference to the TCID<sub>50</sub>. Positive controls were viruses incubated with 50% ethanol, negative controls were viruses incubated in DMEM 2% FBS (culture medium). The protocol for inactivation assay was prepared with reference to <xref rid="B26" ref-type="bibr">Tai et al. (2015)</xref>.</p></sec><sec id="S2.SS9"><title>Statistical Analysis</title><p>Gompertz growth model <italic>y</italic> = <italic>a</italic><italic>exp</italic>&#x02061;(&#x02212;<italic>b</italic><italic>exp</italic>&#x02061;(&#x02212;<italic>c</italic><italic>x</italic>)) and exponential model <italic>y</italic> = <italic>a</italic><italic>exp</italic>&#x02061;(<italic>b</italic><italic>x</italic>) were fitted to estimate the concentration-dependent decrease in virus titer after treatment with EGb and its phytochemical components. Based on those models, <italic>IC</italic><sub><italic>50</italic></sub>(inhibitory concentration) &#x02013; concentration of the extract that inhibited 50% of viral replication when compared to the virus control &#x02013; were calculated. Cytotoxicity of EGb was measured with luminescent and CTEs assay. Concentrations <italic>CC</italic><sub><italic>50</italic></sub> (cytotoxic concentration) &#x02013; concentration of the extract that reduced the cell viability by 50% when compared to untreated control &#x02013; were estimated based on fitted sigmoid curves <inline-formula><mml:math id="INEQ12"><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>b</mml:mi><mml:mo>-</mml:mo><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mrow><mml:mi>exp</mml:mi><mml:mo>&#x02061;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>c</mml:mi><mml:mo>-</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mi>d</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></inline-formula>. Differences in the kinetics of antiviral activity between EGb&#x02019; phytocomponents were measured with the following function <italic>R</italic>(<italic>x</italic>) = <italic>E</italic>(<italic>a</italic><italic>c</italic><italic>t</italic><italic>i</italic><italic>v</italic><italic>i</italic><italic>t</italic><italic>y</italic>|<italic>d</italic>&#x02265;<italic>x</italic>), where <italic>x</italic> &#x02208; {6,15.5,15,20,23,25}&#x003bc;<italic>g</italic>/<italic>m</italic><italic>l</italic>, which is the expected value (i.e., mean) of antiviral activity if concentration <italic>d</italic> is equal or higher than <italic>x</italic>. Confidence intervals for a mean were estimated with bootstrap sampling. The difference between HHV-1 and HHV-2 concentration-dependent decrease in viral titer after treatment with EGb was tested with Hotelling&#x02019;s <italic>T</italic><sup>2</sup>statistic for vectors of Gompertz model parameters. Variance-covariance matrixes were estimated based on bootstrap sampling and degrees of freedom were computed with Nel and van der Merwe method. Selectivity index (SI) is a ratio that measures the window between cytotoxicity and antiviral activity. The higher the SI ratio, the more effective and safe a drug would be during <italic>in vivo</italic> treatment for a given viral infection (<xref rid="B22" ref-type="bibr">Pritchett et al., 2014</xref>). SI was calculated from the ratio CC<sub>50</sub>/IC<sub>50</sub>. Relative concentration <italic>x</italic> was computed as <inline-formula><mml:math id="INEQ15"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>C</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mi>x</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mi>x</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mo>&#x02062;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mn>50</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula>. Cohen&#x02019;s &#x003b3; was used as a measure of effect size for difference between two means.</p></sec></sec><sec id="S3"><title>Results</title><sec id="S3.SS1"><title>Assessment of Non-toxic Concentrations of EGb</title><p>Starting solution of EGb 20 mg/ml in DMSO was diluted to final concentrations of 25&#x02013;1000 &#x003bc;g/ml in DMEM 2% FBS. A549 cells were seeded in a 96-well plate (1.8 &#x000d7; 10<sup>5</sup> cells/ml) and incubated 24 h at 37&#x000b0;C/5% CO<sub>2</sub> incubator to obtain a monolayer. 24-h cultures monolayers of A549 cell with confluence &#x0003e; 90% were treated with serial dilutions of EGb and incubated for 72 h at 37&#x000b0;C/5% CO<sub>2</sub>. Morphological changes of the cells were observed every day under an inverted microscope and cell viability was calculated based on a CTEs scale. The final concentrations of DMSO &#x0003c; 2% were non-toxic. Results are presented in <xref ref-type="supplementary-material" rid="SM2">Supplementary Table S1</xref> (<xref ref-type="supplementary-material" rid="SM1">Supplementary File-Table 2</xref>). Fresh EGb dilutions were prepared each time before starting a series of experiments. EGb in the range of 400 to 1000 &#x003bc;g/ml resulted in high cytotoxicity (CTEs = 3&#x02013;4). Slight cytotoxic effects were observed for EGb in concentrations 200&#x02013;250 &#x003bc;g/ml (CTEs = 1). EGb in the range of 25&#x02013;150 &#x003bc;g/ml was non-toxic for A549 (CTEs = 0). EGb cytotoxicity, measured as a percent of cell viability in function of EGb concentration, was investigated also with luminescent assay for the same concentrations. Control were cells incubated only with culture medium DMEM 2% FBS. <xref ref-type="fig" rid="F1">Figure 1</xref> shows experimental measurements and sigmoid regression curves. Both curves has different slopes, however, estimated cytotoxic concentration of EGb which reduced viability of cells by 50% (CC<sub>50</sub>) was the same for two methods and equal to <italic>C</italic><italic>C</italic><sub>50</sub>&#x02245;381.5&#x003bc;<italic>g</italic>/<italic>m</italic><italic>l</italic> (average).</p><fig id="F1" position="float"><label>FIGURE 1</label><caption><p>Determination of the 50% cytotoxic concentration (CC<sub>50</sub>) of EGb on A549. A549 cells were treated with serial dilutions of EGb (25&#x02013;1000 &#x003bc;g/ml) and incubated for 72 h at 37&#x000b0;C/5% CO<sub>2</sub>. Cells viability were measured with the luminescent assay (<italic>n</italic> = 3) and CTEs assay (<italic>n</italic> = 6). CC<sub>50</sub> was calculated based on fitted sigmoid curves. Error bars are CI95% of the means.</p></caption><graphic xlink:href="fmicb-10-02367-g001"/></fig></sec><sec id="S3.SS2"><title>Antiviral Activity of EGb</title><p>A potential antiviral effect of EGb against herpesviruses HHV-1 and HHV-2 was examined by early viral entry assay (inactivation assay). The test was performed to examine whether EGb could inactivate herpesviruses in cell-free state (free virus particles) and eventually prevent subsequent infection. EGb in the range of 25&#x02013;500 &#x003bc;g/ml was incubated with HHV-1 and HHV-2 by 0.5 h (&#x02018;Short-term&#x02019;), 1 and 2 h (&#x02018;Long-term&#x02019;), and next titrated in A549 cells. Viral titer was calculated with reference to the TCID<sub>50</sub>. The highest dilution of the virus at which the CPEs occurred in about 50% of the cells was determined as 1 TCID<sub>50</sub>. Each variant of the experiment was performed three times in two independent repetitions each. Negative control were viruses incubated only with culture medium DMEM 2% FBS, and positive control were viruses incubated with 50% ethanol, which reduced virus infectivity of over 4 log (efficacy 99,99%). DMSO concentrations &#x02264; 2% did not inactivate HHV-1 and HHV-2. Results are presented in <xref ref-type="supplementary-material" rid="SM2">Supplementary Table S2</xref> (<xref ref-type="supplementary-material" rid="SM1">Supplementary File-Table 2</xref>). EGb in a concentration-dependent manner appeared to interact with the cell-free virions, resulting in irreversible effects that protected the cell monolayer from the subsequent infection. These results suggested that EGb have a direct impact on these free virus particles by inactivating them and neutralizing their infectivity in non-toxic concentrations. EGb decline viral titer even of 4 log TCID<sub>50</sub> which means 99.99% decrease of virus infectivity. With regards to the obtained results, a decrease in viral infectivity (viral titer), i.e., the effectiveness of EGb in inactivation of HHV-1 and HHV-2, was assessed. The ability of EGb to inactivate both viruses was observed already after 0.5 h and increased with the time of incubation (0.5 &#x0003c; 1 &#x0003c; 2 h). In addition, along with the increasing time of EGb incubation with both viruses, the lower concentrations of EGb exhibited prominent antiviral activity. The concentration of EGb which inhibited viral replication in 50% of cells (IC<sub>50</sub>, inhibitory concentration) was calculated on the basis of the time of incubation. In order to evaluate EGb antiviral activity (inactivation efficiency), a selectivity index (SI) was determined according to formula CC<sub>50</sub>/IC<sub>50</sub>. Results are presented in <xref rid="T1" ref-type="table">Table 1</xref>. Additionally, differences in pH of DMEM 2% FBS (medium for EGb dissolution) in selected solutions of EGb which were used in antiviral activity tests were investigated. It was showed that pH was constant during incubation time and did not influence on antiviral activity of EGb. Results are showed in <xref ref-type="supplementary-material" rid="SM2">Supplementary Table S3</xref> (<xref ref-type="supplementary-material" rid="SM1">Supplementary File-Table 2</xref>).</p><table-wrap id="T1" position="float"><label>TABLE 1</label><caption><p>Antiviral activity of EGb against HHV-1 and HHV-2.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="center" colspan="3" rowspan="1"><bold>HHV-1</bold><hr/></td><td valign="top" align="center" colspan="3" rowspan="1"><bold>HHV-2</bold><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Incubation time [h]</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>0.5</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>1</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>2</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>0.5</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>1</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>2</bold></td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">CC<sub>50</sub> [&#x003bc;g/ml]</td><td valign="top" align="center" rowspan="1" colspan="1">381.5</td><td valign="top" align="center" rowspan="1" colspan="1">381.5</td><td valign="top" align="center" rowspan="1" colspan="1">381.5</td><td valign="top" align="center" rowspan="1" colspan="1">381.5</td><td valign="top" align="center" rowspan="1" colspan="1">381.5</td><td valign="top" align="center" rowspan="1" colspan="1">381.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>50</sub> [&#x003bc;g/ml]</td><td valign="top" align="center" rowspan="1" colspan="1">79.1</td><td valign="top" align="center" rowspan="1" colspan="1">68.2</td><td valign="top" align="center" rowspan="1" colspan="1">29.6</td><td valign="top" align="center" rowspan="1" colspan="1">137.3</td><td valign="top" align="center" rowspan="1" colspan="1">45.5</td><td valign="top" align="center" rowspan="1" colspan="1">8.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SI</td><td valign="top" align="center" rowspan="1" colspan="1">4.8</td><td valign="top" align="center" rowspan="1" colspan="1">5.6</td><td valign="top" align="center" rowspan="1" colspan="1">12.8</td><td valign="top" align="center" rowspan="1" colspan="1">2.8</td><td valign="top" align="center" rowspan="1" colspan="1">8.4</td><td valign="top" align="center" rowspan="1" colspan="1">47.1</td></tr></tbody></table><table-wrap-foot><attrib><italic>CC<sub>50</sub> (cytotoxic concentration) &#x02013; concentration of the extract that reduced the cell viability by <italic>50</italic>% when compared to untreated control. IC<sub>50</sub> (inhibitory concentration) - concentration of the extract that inhibited 50% of viral replication when compared to the virus control. SI (selectivity index) &#x02013; calculated from the ratio CC<sub>50</sub>/IC<sub>50</sub>.</italic></attrib></table-wrap-foot></table-wrap></sec><sec id="S3.SS3"><title>Antiviral Activity of <italic>G. biloba</italic> Flavonoids and Terpenes Compared to EGb</title><p>To establish if EGb presented higher antiviral effects than its phytochemical constituents and which fraction (<italic>G. biloba</italic> flavonoids or terpenes) is responsible for anti-herpesviral activity, a comparison of the preparations was performed. In all experiments, flavonoids mix (<italic>G. biloba</italic> flavonoids mix) and terpenes mix (<italic>G. biloba</italic> terpene lactones mix) were examined in concentrations consistent with the total amount in each EGb. Cytotoxicity was determined based on the CTEs scale. Maximum non-toxic concentrations for flavonoids was 25 &#x003bc;g/ml, whereas for terpenes 9 &#x003bc;g/ml (data not shown). Further analysis showed that the observed reduction of viral titer (for both viruses) by EGb was caused by flavonoids rather than terpenes. There was a clear concentration-dependence in HHV-1 as well as HHV-2 titer reduction for flavonoids mix, opposite to terpenes mix, where no relationship was observed and viral titer reduction was vestigial. Compounds were diluted in DMEM with 2% FBS. Negative control were viruses incubated only with culture medium DMEM 2% FBS, and positive control were viruses incubated with 50% ethanol, which reduced virus infectivity of over 4 log (efficacy 99,99%). The final concentrations of methanol &#x02264; 10% were non-toxic. Results are presented in <xref ref-type="supplementary-material" rid="SM2">Supplementary Table S1</xref> (<xref ref-type="supplementary-material" rid="SM1">Supplementary File-Table 2</xref>). The maximal concentration of terpenes mix at 9 &#x003bc;g/ml caused an average reduction in viral titer respectively &#x02212;0.72 logs for HHV-1 and &#x02212;0.74 logs for HHV-2. Virus infectivity decreased <inline-formula><mml:math id="INEQ20"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>18.6</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>&#x02248;</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:math></inline-formula> times compared to controls. <xref ref-type="fig" rid="F2">Figure 2</xref> shows a concentration-dependent reduction in viral titer for EGb and its two constituents: flavonoids mix and terpene mix. Interestingly, as shown in <xref ref-type="fig" rid="F2">Figure 2</xref> and in <xref ref-type="supplementary-material" rid="SM2">Supplementary Table S4</xref>, EGb exhibited higher antiviral activity than flavonoids and terpenes. <xref ref-type="supplementary-material" rid="SM2">Supplementary Table S4</xref> (<xref ref-type="supplementary-material" rid="SM1">Supplementary File-Table 2</xref>) contains the results of average changes in HHV-1 and HHV-2 titer after 2 h of incubation with EGb, flavonoids mix and terpene mix. The results clearly showed that there was a strong effect of EGb. EGb concentration equal to 80 &#x003bc;g/ml reduced HHV-1 average titer of &#x02212;2 logs, i.e., 100 times, but virus titer reduction for 150 &#x003bc;g/ml was <italic>l</italic><italic>o</italic><italic>g</italic><sub>10</sub>(&#x02212;4.23)&#x02192;10<sup>&#x02212;4.23</sup> = 0.000059&#x02192;<italic>r</italic><italic>e</italic><italic>d</italic><italic>u</italic><italic>c</italic><italic>t</italic><italic>i</italic><italic>o</italic><italic>n</italic>:&#x02212;99.9941%, i.e., the activity was <inline-formula><mml:math id="INEQ22"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>5.9</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>16949</mml:mn></mml:mrow></mml:math></inline-formula> times lower compared to control (<italic>c</italic> = 0&#x003bc;<italic>g</italic>/<italic>m</italic><italic>l</italic>). Similar relation was observed for EGb and HHV-2. Methanol concentrations &#x02264; 25% did not inactivate HHV-1 and HHV-2. Results are presented in <xref ref-type="supplementary-material" rid="SM2">Supplementary Table S2</xref> (<xref ref-type="supplementary-material" rid="SM1">Supplementary File-Table 2</xref>).</p><fig id="F2" position="float"><label>FIGURE 2</label><caption><p>Mean reduction of HHV-1 and HHV-2 titer after 2 h of incubation with EGb, and with flavonoids mix and terpenes mix in relation to concentration (<italic>n</italic> = 6). Confidence intervals CI95% for means are presented in <xref ref-type="supplementary-material" rid="SM2">Supplementary Table S4</xref> (<xref ref-type="supplementary-material" rid="SM1">Supplementary File-Table 2</xref>). Viral titer was calculated with reference to the TCID<sub>50</sub>. Reduction of viral titer was defined as difference in logs<sub>10</sub> between concentration and control.</p></caption><graphic xlink:href="fmicb-10-02367-g002"/></fig></sec><sec id="S3.SS4"><title>Comparison of Antiviral Action of Isorhamnetin, Kaempferol, and Quercetin</title><p>Based on the results presented above, it was established that antiviral activity of EGb probably depends mostly on flavonoids. It was justified, therefore, to determine if particular flavonoids may express anti-herpesviral activity. <xref ref-type="supplementary-material" rid="SM2">Supplementary Table S5</xref> (<xref ref-type="supplementary-material" rid="SM1">Supplementary File-Table 2</xref>) presents the mean change in virus titer after incubation with flavonoids mix and particular flavonoids, i.e., isorhamnetin, kaempferol, and quercetin. The results of the analysis showed a strong concentration-dependent reduction of HHV-1 and HHV-2 titer only for isorhamnetin. For concentration <italic>d</italic> = 5&#x003bc;<italic>g</italic>/<italic>m</italic><italic>l</italic> HHV-1 titer decreased by <italic>l</italic><italic>o</italic><italic>g</italic><sub>10</sub>(&#x02212;3.44)&#x02192;10<sup>&#x02212;3.44</sup> = 0.000363&#x02192;<italic>r</italic><italic>e</italic><italic>d</italic><italic>u</italic><italic>c</italic><italic>t</italic><italic>i</italic><italic>o</italic><italic>n</italic>:&#x02212;99.964%, i.e., the activity was <inline-formula><mml:math id="INEQ26"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>3.63</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>2754</mml:mn></mml:mrow></mml:math></inline-formula> times lower compared to concentration <italic>d</italic> = 0&#x003bc;<italic>g</italic>/<italic>m</italic><italic>l</italic> (control). On the contrary, at a concentration of <italic>d</italic> = 6&#x003bc;<italic>g</italic>/<italic>m</italic><italic>l</italic> HHV-1 titer decreased <italic>l</italic><italic>o</italic><italic>g</italic><sub>10</sub>(&#x02212;0.89)&#x02192;10<sup>&#x02212;0.89</sup> = 0.13&#x02192;<italic>r</italic><italic>e</italic><italic>d</italic><italic>u</italic><italic>c</italic><italic>t</italic><italic>i</italic><italic>o</italic><italic>n</italic>:&#x02212;87.11%, i.e., the activity was only <inline-formula><mml:math id="INEQ30"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1.29</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>&#x02245;</mml:mo><mml:mn>8</mml:mn></mml:mrow></mml:math></inline-formula> times lower compared to concentration <italic>d</italic> = 0&#x003bc;<italic>g</italic>/<italic>m</italic><italic>l</italic> (control). Similar results were obtained for HHV-2. There was no concentration-dependent effect for kaempferol and quercetin. The reduction of HHV-1 and HHV-2 titer was smaller for the highest concentrations, and smaller than the reduction of viral titer by isorhamnetin at the smallest concentration. Flavonoids mix inactivated HHV-1 and HHV-2 much more than kaempferol and quercetin, however much less than isorhamnetin (<xref ref-type="fig" rid="F3">Figure 3</xref>). Compounds were diluted in DMEM with 2% FBS. In those experiments negative control were viruses incubated only with culture medium DMEM 2% FBS, and positive control were viruses incubated with 50% ethanol, which reduced virus infectivity of over 4 log (efficacy 99,99%).</p><fig id="F3" position="float"><label>FIGURE 3</label><caption><p>Average decrease of HHV-1 and HHV-2 titer (in <italic>log</italic><sub><italic>10</italic></sub>) after 2 h of incubation with flavonoids mix, isorhamnetin, kaempferol, and quercetin compared to controls in relation to concentrations (<italic>n</italic> = 6). Average difference <italic>treatment-control</italic> was showed as the mean of decrease <italic>i</italic><italic>f</italic><italic>c</italic><italic>o</italic><italic>n</italic><italic>c</italic><italic>e</italic><italic>n</italic><italic>t</italic><italic>r</italic><italic>a</italic><italic>t</italic><italic>i</italic><italic>o</italic><italic>n</italic>&#x02265;<italic>x</italic>, <italic>w</italic><italic>h</italic><italic>e</italic><italic>r</italic><italic>e</italic><italic>x</italic> &#x02208; {6,12.5,15,20,23,25}&#x003bc;<italic>g</italic>/<italic>m</italic><italic>l</italic>. Confidence intervals CI95% for averages are presented in <xref ref-type="supplementary-material" rid="SM2">Supplementary Table S5</xref> (<xref ref-type="supplementary-material" rid="SM1">Supplementary File-Table 2</xref>). Viral titer was calculated with reference to the TCID<sub>50</sub>. Reduction of viral titer was defined as difference in logs<sub>10</sub> between concentration and control.</p></caption><graphic xlink:href="fmicb-10-02367-g003"/></fig><p>To present the difference in the kinetics of antiviral action for izorhamnetin, kaempferol and quercetin, let introduce the function <italic>R</italic>(<italic>x</italic>) = <italic>E</italic>[<italic>a</italic><italic>c</italic><italic>t</italic><italic>i</italic><italic>v</italic><italic>i</italic><italic>t</italic><italic>y</italic>|<italic>d</italic>&#x02265;<italic>x</italic>], <italic>x</italic> &#x02208; {6,12.5,15,20,23,25}&#x003bc;<italic>g</italic>/<italic>m</italic><italic>l</italic>, which is the expected value (i.e., mean) reduction of HHV-1 and HHV-2 titer if concentration <italic>d</italic> is equal or higher than <italic>x</italic>. The results, calculated for every concentration based on data from <xref ref-type="supplementary-material" rid="SM2">Supplementary Table S5</xref> (<xref ref-type="supplementary-material" rid="SM1">Supplementary File-Table 2</xref>), are presented on <xref ref-type="fig" rid="F3">Figure 3</xref>. For example, the average decrease for <italic>x</italic> = 6&#x003bc;<italic>g</italic>/<italic>m</italic><italic>l</italic> is the mean difference for concentrations &#x02265;6, i.e., simply, it is the general mean for all experiments. The second point is the mean difference for concentrations &#x02265;12.5 and so on. The last point is the mean of decrease at a higher concentration <italic>x</italic> = 25&#x003bc;<italic>g</italic>/<italic>m</italic><italic>l</italic>. Results for both viruses are similar. As mentioned above, among three flavonoids only isorhamnetin decreased HHV-1 and HHV-2 titer and concentration-dependent decreasing had a quadratic relationship. For isorhamnetin concentration <italic>x</italic> = 25&#x003bc;<italic>g</italic>/<italic>m</italic><italic>l</italic> confidence interval for mean decrease of HHV-1 titer was CI95% (&#x02212;3.89; &#x02212;3), certainly a population (unknown) decrease is at least 1,000 times and no higher than 7,700 times compared to control. For HHV-2, these effects were similar, i.e., CI95% (&#x02212;3.78; &#x02212;3.11).</p></sec><sec id="S3.SS5"><title>Efficiency of EGb and Isorhamnetin in Impeding of HHV-1 and HHV-2 Primary Infection</title><p>A comparative analysis was also performed for evaluation of antiviral activity of EGb and isorhamnetin, the flavonoid that expressed the highest anti-herpesviral action. Cytotoxicity of isorhamnetin was estimated based on CTEs assay. CC<sub>50</sub> for isorhamnetin was <inline-formula><mml:math id="INEQ41"><mml:mrow><mml:mrow><mml:mi>C</mml:mi><mml:mo>&#x02062;</mml:mo><mml:msubsup><mml:mi>C</mml:mi><mml:mn>50</mml:mn><mml:mrow><mml:mi>I</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>s</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>o</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mn>61.85</mml:mn><mml:mo>&#x02062;</mml:mo><mml:mi mathvariant="normal">&#x003bc;</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>g</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mi>m</mml:mi></mml:mrow><mml:mo>&#x02062;</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>. To compare the effectiveness of EGb and isorhamnetin in the inactivation of HHV-1 and HHV-2, two independent conditions must be met. First, any considered concentrations had to correspond to 100% cells viability, and second, concentrations expressed relative to CC<sub>50</sub> had to be the same for EGb and isorhamnetin. Based on cytotoxicity results for EGb and isorhamnetin in CTEs assay, the highest accepted concentration for EGb equal to 125&#x003bc;<italic>g</italic>/<italic>m</italic><italic>l</italic> (<xref ref-type="fig" rid="F1">Figure 1</xref>) was taken. It gave the relative concentration <inline-formula><mml:math id="INEQ43"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>&#x02062;</mml:mo><mml:msup><mml:mi>C</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>G</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mn>125</mml:mn><mml:mn>381.5</mml:mn></mml:mfrac><mml:mo>=</mml:mo><mml:mn>0.327</mml:mn></mml:mrow></mml:math></inline-formula>. Based on these results, the highest accepted concentration for isorhamnetin could not be higher than <inline-formula><mml:math id="INEQ44"><mml:mrow><mml:mn>0.327</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>C</mml:mi><mml:msubsup><mml:mi>C</mml:mi><mml:mn>50</mml:mn><mml:mrow><mml:mi>I</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>s</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>o</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>61.85</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>20.3</mml:mn><mml:mi mathvariant="normal">&#x003bc;</mml:mi><mml:mi>g</mml:mi><mml:mo>/</mml:mo><mml:mi>m</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:math></inline-formula>. The concentration of isorhamnetin equal to 20&#x003bc;<italic>g</italic>/<italic>m</italic><italic>l</italic> manifested in 100% cells viability, so we had <inline-formula><mml:math id="INEQ46"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mo>&#x02062;</mml:mo><mml:msup><mml:mi>C</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>s</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>o</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mn>20</mml:mn><mml:mn>61.85</mml:mn></mml:mfrac><mml:mo>=</mml:mo><mml:mn>0.323</mml:mn></mml:mrow></mml:math></inline-formula>. Results presented in <xref ref-type="supplementary-material" rid="SM2">Supplementary Tables S4</xref>, <xref ref-type="supplementary-material" rid="SM2">S5</xref> (<xref ref-type="supplementary-material" rid="SM1">Supplementary File-Table 2</xref>) clearly show that for the same relative concentrations, EGb caused a reduction of HHV-1 and HHV-2 titer by &#x02212;3.99<italic>log</italic>TCID<sub>50</sub>, which is much higher compared to isorhamnetin. Flavonoid reduced HHV-1 titer about &#x02212;1.67<italic>log</italic> TCID<sub>50</sub> and HHV-2 about &#x02212;1.89<italic>log</italic> TCID<sub>5</sub><sub>0</sub> respectively. Isorhamnetin in a concentration of 25&#x003bc;<italic>g</italic>/<italic>m</italic><italic>l</italic> reduced viral titer about &#x02212;3.44<italic>log</italic> TCID<sub>50</sub> for both viruses and this is 0.4 of <inline-formula><mml:math id="INEQ52"><mml:mrow><mml:mi>C</mml:mi><mml:mo>&#x02062;</mml:mo><mml:msubsup><mml:mi>C</mml:mi><mml:mn>50</mml:mn><mml:mrow><mml:mi>I</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>s</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>o</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> (i.e., closer to<italic>CC</italic><sub><italic>50</italic></sub>), but still the titer reduction is about 6 times weaker compared to EGb in concentration equal to 125&#x003bc;<italic>g</italic>/<italic>m</italic><italic>l</italic>. Based on the data presented in <xref ref-type="supplementary-material" rid="SM2">Supplementary Tables S4</xref>, <xref ref-type="supplementary-material" rid="SM2">S5</xref> (<xref ref-type="supplementary-material" rid="SM1">Supplementary File-Table 2</xref>), the estimated <inline-formula><mml:math id="INEQ54"><mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mo>&#x02062;</mml:mo><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>&#x02062;</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>I</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>s</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>o</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>H</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>V</mml:mi></mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mn>8.37</mml:mn><mml:mo>&#x02062;</mml:mo><mml:mi mathvariant="normal">&#x003bc;</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>g</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mi>m</mml:mi></mml:mrow><mml:mo>&#x02062;</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="INEQ55"><mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mo>&#x02062;</mml:mo><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>&#x02062;</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>I</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>s</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>o</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>H</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>V</mml:mi></mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mn>7.08</mml:mn><mml:mo>&#x02062;</mml:mo><mml:mi mathvariant="normal">&#x003bc;</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>g</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mi>m</mml:mi></mml:mrow><mml:mo>&#x02062;</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> for isorhamnetin, and <inline-formula><mml:math id="INEQ56"><mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mo>&#x02062;</mml:mo><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>&#x02062;</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>E</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>G</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>b</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>H</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>V</mml:mi></mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mn>31.65</mml:mn><mml:mo>&#x02062;</mml:mo><mml:mi mathvariant="normal">&#x003bc;</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>g</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mi>m</mml:mi></mml:mrow><mml:mo>&#x02062;</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="INEQ57"><mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mo>&#x02062;</mml:mo><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>&#x02062;</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>E</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>G</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>b</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>H</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>V</mml:mi></mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mn>18.71</mml:mn><mml:mo>&#x02062;</mml:mo><mml:mi mathvariant="normal">&#x003bc;</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>g</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mi>m</mml:mi></mml:mrow><mml:mo>&#x02062;</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> for EGb. Results are shown in <xref rid="T2" ref-type="table">Table 2</xref>. Confidence intervals CI95% for IC<sub>50</sub> were <italic>C</italic><italic>I</italic>95(20.7,42.8) and <italic>C</italic><italic>I</italic>95(10.3,29.4) for HHV-1 and HHV-2, respectively. Difference <inline-formula><mml:math id="INEQ60"><mml:mrow><mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mo>&#x02062;</mml:mo><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>&#x02062;</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>E</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>G</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>b</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>H</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>V</mml:mi></mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mi>I</mml:mi><mml:mo>&#x02062;</mml:mo><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>&#x02062;</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>E</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>G</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>b</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>H</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>V</mml:mi></mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mn>12.94</mml:mn><mml:mo>&#x02062;</mml:mo><mml:mi mathvariant="normal">&#x003bc;</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>g</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mi>m</mml:mi></mml:mrow><mml:mo>&#x02062;</mml:mo><mml:mi>l</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> with confidence interval <italic>C</italic><italic>I</italic>95(&#x02212;3.5;29.4), statistic <italic>z</italic> = 1.54 for this difference and <italic>p</italic> = 0.1238, so there was no proof that IC<sub>50</sub> for both HHV-1 and HHV-2 was different. The precision of estimation of this difference was measured with Cohen&#x02019;s <italic>&#x003b3;</italic> effect-size and gave the result &#x003b3; = 2.18 with [CI95(2.13, 2.21)]; therefore, according to Sawilowsky&#x02019;s interpretation, this effect was huge (<xref rid="B25" ref-type="bibr">Shlomo, 2009</xref>). <xref ref-type="fig" rid="F4">Figure 4</xref> shows a concentration-dependent reduction of HHV-1 and HHV-2 titer after 2 h of incubation with EGb and isorhamnetin. We can see that fitted curves for EGb differ between HHV-1 and HHV-2; however, such difference is not obtained for isorhamnetin. Our next questions naturally involved whether two curves for EGb statistically differ or not. Hotelling&#x02019;s <italic>T</italic><sup>2</sup> statistic for vectors of the parameters of the two curves is <inline-formula><mml:math id="INEQ65"><mml:mrow><mml:msup><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mn>3.86</mml:mn><mml:mo>&#x0223c;</mml:mo><mml:msubsup><mml:mi mathvariant="normal">&#x003c7;</mml:mi><mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mo>&#x02062;</mml:mo><mml:mi>f</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mn>1.9</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&#x02192;</mml:mo><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.0494</mml:mn></mml:mrow></mml:math></inline-formula>. We can conclude that probably kinetic of EGb activity differs for HHV-1 and HHV-2. Trace of this difference can be seen also in <xref ref-type="fig" rid="F3">Figure 3</xref>. In addition, HHV-2 was more sensitive to quercetin than HHV-1. However, we cannot reject the hypothesis that there were interactions between particular EGb&#x02032; constituents and the general effect of EGb was not a sum of effects of its phytochemical constituents.</p><table-wrap id="T2" position="float"><label>TABLE 2</label><caption><p>Effectiveness of EGb and isorhamnetin in inactivation of HHV-1 and HHV-2.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Compound</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Concentration</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>CC<sub>50</sub></bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Relative concentration</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Cell viability</bold></td><td valign="top" align="center" colspan="2" rowspan="1"><bold>Mean of viral</bold><hr/></td><td valign="top" align="center" colspan="2" rowspan="1"><bold>IC<sub>50</sub></bold><hr/></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"><bold>[&#x003bc;g/ml]</bold></td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"><bold>(% of CC<sub>50</sub>)</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>(CTEs assay)</bold></td><td valign="top" align="center" colspan="2" rowspan="1"><bold>titer reduction</bold></td><td valign="top" colspan="2" rowspan="1"/></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"><bold>HHV-1</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>HHV-2</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>HHV-1</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>HHV-2</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EGb</td><td valign="top" align="center" rowspan="1" colspan="1">125</td><td valign="top" align="center" rowspan="1" colspan="1">381.5</td><td valign="top" align="center" rowspan="1" colspan="1">32.7</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;3.99</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;3.99</td><td valign="top" align="center" rowspan="1" colspan="1">31.65</td><td valign="top" align="center" rowspan="1" colspan="1">18.71</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Isorhamnetin</td><td valign="top" align="center" rowspan="1" colspan="1">20</td><td valign="top" align="center" rowspan="1" colspan="1">61.85</td><td valign="top" align="center" rowspan="1" colspan="1">32.3</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;1.67</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;1.89</td><td valign="top" align="center" rowspan="1" colspan="1">8.37</td><td valign="top" align="center" rowspan="1" colspan="1">7.08</td></tr></tbody></table></table-wrap><fig id="F4" position="float"><label>FIGURE 4</label><caption><p>Fitted curves estimated for concentration-dependent decreasing of for HHV-1 and HHV-2 titers after 2 h of incubation with EGb and isorhamnetin. Gompertz growth model and exponential model was fitted for EGb and isorhamnetin, respectively. The marks on the x-axis on left graph increase logarithmically. Viral titer was calculated with reference to the TCID<sub>50</sub>.</p></caption><graphic xlink:href="fmicb-10-02367-g004"/></fig></sec></sec><sec id="S4"><title>Discussion</title><p>An awareness of the potential opportunities in new therapies for herpesviruses HHV-1 and HHV-2 infections has developed. Some drugs for the management of herpesviruses infections, such as acyclovir, are currently available. However, due to the prevalence of resistance in acyclovir-treated immunocompromised individuals, there is a need to search for new preparations with anti-herpes activity. The overarching goal of developing novel prophylactics or therapeutics against HHV-1 and HHV-2 is to prevent the initial infection or viral cell-to-cell spread. Plant extracts offer safe platforms for the discovery of efficient and novel antiviral agents. One of the promising plant-derived anti-herpesviral agent &#x02013; extract of <italic>G. biloba</italic> (EGb) &#x02013; has been summarized in this paper. In the light of obtained results, EGb could prove a valuable prophylactic and therapeutic in humans.</p><p>The current state of research suffers deficiencies in studies demonstrating antiviral activity of EGb against herpesviruses such as HHV-1 and HHV-2. Limited investigations showed anti-human influenza virus or anti-HIV activity of <italic>G. biloba</italic> preparations. However, this data does not always refer to the dry leaves extract, but rather to other constituents obtained from <italic>G. biloba</italic>, such as polyphenols or organic acids as mentioned above. Importantly, depending on the plant origin and method of extraction, the final products can differ significantly in their activity (<xref rid="B15" ref-type="bibr">Kressmann et al., 2002</xref>). In addition, authors who present the antiviral activity of EGb or other <italic>G. biloga</italic> constituents frequently derive the preparations using small-scale laboratory methods. It is difficult then to establish standardization. This problem also refers to other botanical extracts with potential anti-herpesviruses activity, e.g., hydroalcoholic extract prepared from roots of <italic>Hemidesmus indicus</italic> (<xref rid="B6" ref-type="bibr">Bonvicini et al., 2018</xref>). The extract, however, exhibited high anti-HHV-1 and anti-HHV-2 activity at non-cytotoxic concentrations. Additionally, it should be underlined that EGb patent has expired and many pharmaceutical companies produce preparations that differ from each other in composition and therapeutic properties (<xref rid="B10" ref-type="bibr">Isah, 2015</xref>). The first benefit of EGb investigated in this study is its accessibility and composition. This is a standardized extract, prepared according to the European Pharmacopoeia (Ph. Eur. 8.0) [see section &#x0201c;EGb Characterization&#x0201d; (<xref ref-type="supplementary-material" rid="SM1">Supplementary File-Table 1</xref>)].</p><p>Preparations with valuable antiviral activity must inhibit the growth of a virus without exerting toxicity on the infected cells. We used the microscopic method, CTEs and luminescence method to determine the non-toxic concentrations of EGb before commencing with antiviral activity investigations. With regards to adherent lines, cells that have separated from the surface may still be metabolically active but recognized as undergoing CTEs. In the luminescence test, therefore, we could obtain higher cell viability. Although the CTEs method is more rigorous compared to other cellular tests, in our calculations the estimated CC<sub>50</sub> was the same for two methods (average was 381.5 &#x003bc;g/ml). EGb was non-toxic for living cells up to 150 ug/ml, only slight toxic effects were observed for concentrations ranging from 200 to 250 &#x003bc;g/ml. Importantly, all non-toxic concentrations of EGb showed prominent antiviral activity against HHV-1 and HHV-2, which is the second benefit of this extract. Antiviral activity of other plant-derived compounds, such as biflavone ginkgetin from <italic>Cephalotaxus drupacea</italic>, against herpesviruses have been previously reported (<xref rid="B9" ref-type="bibr">Hayashi et al., 1992</xref>). There are, however, some limitations in the use of such preparations due to their action across a broad range of sub-cytotoxic concentrations.</p><p>Since viral entry into target cell is an important step in the viral replicative cycle, blocking this mechanism can lead to the suppression of HHV-1 and HHV-2 infectivity and provide novel antiviral strategy. Herpesvirus entry into the cell is a complex process that starts with the attachment of positively charged viral glycoproteins gB and/or gC with negatively charged HS proteoglycans (HSPG) present on the cell surface. Viral nucleocapsid is next transported to the nucleus where viral DNA is replicated (<xref rid="B2" ref-type="bibr">Agelidis and Shukla, 2015</xref>). Both herpesviruses were significantly inhibited by pretreatment with EGb prior to the infection of cells, which indicates that EGb affected the virus before adsorption to cell surface. We have shown that EGb is highly effective in diminishing the infectivity of both HHV-1 and HHV-2 in <italic>in vitro</italic> models of infection by direct inactivation of virions. Even by 4 log TCID<sub>50</sub> reduction of both viruses titer with 125 ug/ml EGb was observed, which means a 99.99% decrease in infectivity. Interestingly, EGb strongly inactivated HHV-1 just after 30 min of incubation. Along with the time of incubation, the capacity of EGb to inactivate HHV-1 and HHV-2 increased. This mechanism &#x02013; viral particles trapping &#x02013; lets us hamper the initial infection which in turn may prevent cell-to-cell spread. Possibly, the mechanism of EGb action might be similar as those recently discovered for zinc oxide tetrapods (<xref rid="B19" ref-type="bibr">Mishra et al., 2011</xref>; <xref rid="B3" ref-type="bibr">Antoine et al., 2012</xref>). It has been revealed that this nanostructures can bind up positively charged viral glycoproteins involved in attaching to cell surface, thus decreasing cell&#x02013;virus interactions. Another possible mechanisms are interference in envelope, proteins and/or genome structure of the virus. Maybe the EGb action lead to render the genome non-replicable or inhibit host-cell recognition/binding. Modifications in the virus proteins or genome may lead to the inhibition of these functions and eventually inactivation viral particles. These mechanisms are characteristics for disinfectants (<xref rid="B30" ref-type="bibr">Wigginton et al., 2012</xref>). It should be noticed, however, that disinfectants act often in high toxic concentrations, whereas EGb inactivate viruses in non-toxic concentrations. Future experiments to confirm this mechanism for EGb should be carried out.</p><p>We have investigated antiviral activity of EGb against different viruses belonging to different taxonomic groups, i.e., VSV &#x02013; <italic>Vesicular stomatitis virus</italic>; Indiana strain; ATTC VR-1238<sup>TM</sup>, <italic>Rabdoviridae (enveloped, RNA);</italic> ECBO &#x02013; <italic>Enteric cytopathogenic bovine orphan virus</italic>; LCR-4 strain; ATTC VR-248<sup>TM</sup>, <italic>Picornaviridae (non-enveloped, RNA);</italic> HAdV-5 &#x02013; <italic>Human adenowirus 5</italic>; Adenoid 75 strain; ATTC VR-5<sup>TM</sup>, <italic>Adenoviridae (non-enveloped, DNA</italic>). To investigate influence of EGb on viruses replication steps (i.e., handicap viruses adsorption to the cells surface by blocking appropriate receptors, block out activity of replication enzymes, induction of antiviral conditions in the cells, impeding release of free viral particles from the cells) three antiviral assays (AVA) have been carried out: cell incubation with EGb before viruses adsorption, cell incubation with viruses and EGb simultaneously, and cell incubation with EGb after viruses adsorption. Direct antiviral effect &#x02013; inactivation of free viral particles was also investigated. EGb did not express antiviral activity against none of these viruses. It should be underlined, however, that among tested viruses strong antiviral activity of EGb were observed only for herpesviruses HHV-1 and HHV-2 (DNA, enveloped). Admittedly EGb did not act before and after HHV-1 and HHV-2 penetration into the host cell [data presented in <xref ref-type="supplementary-material" rid="SM2">Supplementary Table S6</xref> (<xref ref-type="supplementary-material" rid="SM1">Supplementary File-Table 2</xref>)], the extract, however, was capable of exerting a direct antiviral effect on herpesviruses free particles. The high reduction of HHV-1 and HHV-2 titer by EGb is another benefit of the extract compared to the other extracts with anti-herpesviral activity. Direct treatment of HHV-1 with <italic>Mentha pulegium</italic> extract was shown to resulted in 1.7 log TCID<sub>50</sub> reduction in virus titers after 1 h (<xref rid="B21" ref-type="bibr">Parsania et al., 2017</xref>). Nevertheless, an effect similar to that of EGb was obtained for <italic>Melissa officinalis</italic> essential oil (<xref rid="B24" ref-type="bibr">Schnitzler et al., 2008</xref>). Melissa oil was capable of exerting a direct antiviral effect on herpesviruses. It affected the virus before adsorption, but not after penetration into the host cell. Melissa oil reduced HHV-1 and HHV-2 titer by 98.8 and 97.2%, respectively.</p><p>Our next questions naturally involved which phytochemical constituents of EGb -flavonoids or terpenes- were responsible for the anti-herpesviral activity of EGb. Flavonoids and terpene lactones from <italic>G. biloba</italic> are the primary compounds that are extensively studied due to their variety of pharmacological activities. Based on the results from inactivation assay, we showed that flavonoids rather than terpene lactones were responsible for anti-HHV-1 and anti-HHV-2 activity. Nevertheless, the observed antiviral activity (inactivation of free viruses particles) was lower for flavonoids mix and terpenes mix than for EGb. The tested <italic>G. biloba</italic> flavonoids mix contained the three most important flavonols, i.e., isorhamnetin, kaempferol, and quercetin. Next, we investigated the antiviral activity of these three compounds. We had expected the antiviral activity of flavonoids fraction against herpesviruses due to previously described antiviral effects of different plant-derived flavonoids. Anti-HHV-1 effects of quercetin and kaempferol from <italic>Ficus benjamina</italic> leaves has been previously reported (<xref rid="B31" ref-type="bibr">Yarmolinsky et al., 2012</xref>). However, we did not confirm such activity for quercetin and kaempferol from <italic>G. biloba.</italic> Surprisingly, prominent antiviral effect was noticed for isorhamnetin. We showed that isorhamnetin has a strong ability to inactivate HHV-1 and HHV-2. Biological activities of isorhamnetin, such as antioxidant, anticancer, antimicrobial, and anti-inflammatory effects, are well described (<xref rid="B14" ref-type="bibr">Kandakumar and Manju, 2017</xref>). Studies of antiviral activity, however, are limited. Isorhamnetin showed antiviral effect against influenza virus. It has been established in both <italic>in vitro</italic> and <italic>in vivo</italic> studies that isorhamnetin acts via direct hemagglutinin (HA) and neuraminidase (NA) inhibition, and direct or indirect inhibition of the expression of viral HA and NA gene (<xref rid="B1" ref-type="bibr">Abdal Dayem et al., 2015</xref>). Several other flavonoids have been described for their antiviral activity (<xref rid="B16" ref-type="bibr">Kumar and Pandey, 2013</xref>). It is expected that, because flavonoids are widely distributed in plants, they should express minimal toxicity. Nevertheless, these compounds have a diverse range of activities for living cells. Antiviral activity but with high cytotoxicity can limit the practical usefulness of most flavonoids and plant extracts presented in scientific literature.</p><p>The results obtained with isorhamnetin and EGb, however, raised the question which of these preparations is more effective in diminishing herpes viruses infectivity. This prompted us to compare the antiviral activity of these two preparations. Analysis revealed interesting results showing that anti-HHV-1 and anti-HHV-2 activity of EGb was much higher compared to isorhamnetin. Moreover, EGb had lower toxicity. These EGb&#x02032; features allow it to be considered as more promising in the treatment of HHV-1 and HHV-2 infections. The study, however, has one limitation. In regards to the lack of significant anti-herpesviral activity of terpenes mix, each component&#x02019;s antiviral effects, i.e., bilobalid, ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J, have not been analyzed. However, it was revealed that flavonoids are the main fraction responsible for anti-herpesviral activity, with the highest activity for isorhamnetin. Importantly, it should be underlined that EGb is a complex compound that consists of several components. Possibly, combined effects of its constituents decide about strong anti HHV-1 and anti-HHV-2 activity.</p><p>The potential use of EGb in multidrug therapy with synthetic anti-herpes compounds can be considered. The genetic diversity of herpesvirus genomes within an infected individual is now well-established, and this is often related to resistance to current antiviral drugs. Eventually, EGb may be prospectively considered and implemented in combination therapy with standard antivirals when the suppression of viral replication provided by this preparations is not complete, and cannot be supported by the immune system in immunocompromised hosts or in conditions where the immune system is thought to be a key factor in the development of the disease. This <italic>in vitro</italic> studies showed very interesting activity of EGb and its phytochemical constituents. Future <italic>in vivo</italic> investigations, however, are needed to confirm EGb efficacy. Latent HHV-1 in the brain may be reactivated intermittently by events such as immunosuppression, peripheral infection, and inflammation, the consequent accumulating damage culminates eventually in the development of AD. It is true that, at the moment, there is not enough evidence to know whether treating infections would be a good strategy to treat AD or to reduce the risk of the disease. This is why further research is needed to shed more light on this important topic.</p></sec><sec id="S5"><title>Conclusion</title><p>In summary, standardized EGb shows high anti-HHV-1 and anti-HHV-2 activity in non-toxic concentrations and significantly reduces the infectivity of both pathogens. Most likely, EGb could augment current therapies for herpes labialis and genital herpes, especially in the treatment of skin ailments during recurrent infections. A combination of antiviral agents with different molecular targets, including EGb, has the potential to keep HHV-1 and HHV-2 replication to a minimum.</p></sec><sec sec-type="data-availability" id="S6"><title>Data Availability Statement</title><p>All datasets generated for this study are included in the manuscript/<xref ref-type="supplementary-material" rid="SM3">Supplementary Files</xref>.</p></sec><sec id="S7"><title>Author Contributions</title><p>MarS and JL: conceptualization, funding acquisition, project administration, and supervision. MarS, MacS, and MO: data curation. MarS and MacS: formal analysis and visualization. MO, KZ, and MarS: investigations. MarS, MO, and KZ: methodology. MarS, MacS, and JL: writing &#x02013; original draft, review, and editing.</p></sec><sec id="conf1"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This work was supported by internal research funds of the Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, and Wroc&#x00142;aw Medical University.</p></fn></fn-group><ack><p>The authors wish to acknowledge Dominika Pilichowska, Olga B&#x00142;achowicz, and Piotr Naporowski for their prominent technical assistance.</p></ack><sec id="S10" sec-type="supplementary material"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmicb.2019.02367/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fmicb.2019.02367/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Table_1.DOCX"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM2"><media xlink:href="Table_2.DOCX"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM3"><media xlink:href="Data_Sheet_1.CSV"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdal Dayem</surname><given-names>A.</given-names></name><name><surname>Choi</surname><given-names>H. Y.</given-names></name><name><surname>Kim</surname><given-names>Y. B.</given-names></name><name><surname>Cho</surname><given-names>S.-G.</given-names></name></person-group> (<year>2015</year>). <article-title>Antiviral effect of methylated flavonol isorhamnetin against influenza.</article-title>
<source><italic>PLoS One</italic></source>
<volume>10</volume>:<issue>e0121610</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0121610</pub-id>
<?supplied-pmid 25806943?><pub-id pub-id-type="pmid">25806943</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agelidis</surname><given-names>A. M.</given-names></name><name><surname>Shukla</surname><given-names>D.</given-names></name></person-group> (<year>2015</year>). <article-title>Cell entry mechanisms of HSV: what we have learned in recent years.</article-title>
<source><italic>Future Virol.</italic></source>
<volume>10</volume>
<fpage>1145</fpage>&#x02013;<lpage>1154</lpage>. <pub-id pub-id-type="doi">10.2217/fvl.15.85</pub-id>
<?supplied-pmid 27066105?><pub-id pub-id-type="pmid">27066105</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antoine</surname><given-names>T. E.</given-names></name><name><surname>Mishra</surname><given-names>Y. K.</given-names></name><name><surname>Trigilio</surname><given-names>J.</given-names></name><name><surname>Tiwari</surname><given-names>V.</given-names></name><name><surname>Adelung</surname><given-names>R.</given-names></name><name><surname>Shukla</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>96</volume>
<fpage>363</fpage>&#x02013;<lpage>375</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2012.09.020</pub-id>
<?supplied-pmid 23047013?><pub-id pub-id-type="pmid">23047013</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birkmann</surname><given-names>A.</given-names></name><name><surname>Zimmermann</surname><given-names>H.</given-names></name></person-group> (<year>2016</year>). <article-title>HSV antivirals - current and future treatment options.</article-title>
<source><italic>Curr. Opin. Virol.</italic></source>
<volume>18</volume>
<fpage>9</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2016.01.013</pub-id>
<?supplied-pmid 26897058?><pub-id pub-id-type="pmid">26897058</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Boldogh</surname><given-names>I.</given-names></name><name><surname>Albrecht</surname><given-names>T.</given-names></name><name><surname>Porter</surname><given-names>D. D.</given-names></name></person-group> (<year>1996</year>). &#x0201c;<article-title>Persistent viral infections</article-title>,&#x0201d; in <source><italic>Medical Microbiology</italic></source>, <role>ed.</role>
<person-group person-group-type="editor"><name><surname>Baron</surname><given-names>S.</given-names></name></person-group>, (<publisher-loc>Galveston, TX</publisher-loc>: <publisher-name>University of Texas Medical Branch at Galveston</publisher-name>).</mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonvicini</surname><given-names>F.</given-names></name><name><surname>Lianza</surname><given-names>M.</given-names></name><name><surname>Mandrone</surname><given-names>M.</given-names></name><name><surname>Poli</surname><given-names>F.</given-names></name><name><surname>Gentilomi</surname><given-names>G. A.</given-names></name><name><surname>Antognoni</surname><given-names>F.</given-names></name></person-group> (<year>2018</year>). <article-title><italic>Hemidesmus indicus</italic> (L.) R. Br. extract inhibits the early step of herpes simplex type 1 and type 2 replication.</article-title>
<source><italic>New Microbiol.</italic></source>
<volume>41</volume>
<fpage>187</fpage>&#x02013;<lpage>194</lpage>. <?supplied-pmid 29874387?><pub-id pub-id-type="pmid">29874387</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cre&#x00163;u</surname><given-names>F. M.</given-names></name><name><surname>St&#x00103;noiu</surname><given-names>B. P.</given-names></name><name><surname>Pisoschi</surname><given-names>C. G.</given-names></name><name><surname>Predescu</surname><given-names>A. M.</given-names></name><name><surname>R&#x00103;u</surname><given-names>G.</given-names></name></person-group> (<year>2017</year>). <article-title>Biological evaluation of two 1,4-naphthoquinone derivatives against a breast human adenocarcinoma cell line.</article-title>
<source><italic>Curr. Health Sci. J.</italic></source>
<volume>43</volume>
<fpage>335</fpage>&#x02013;<lpage>339</lpage>. <pub-id pub-id-type="doi">10.12865/CHSJ.43.04.08</pub-id>
<?supplied-pmid 30595899?><pub-id pub-id-type="pmid">30595899</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haruyama</surname><given-names>T.</given-names></name><name><surname>Nagata</surname><given-names>K.</given-names></name></person-group> (<year>2013</year>). <article-title>Anti-influenza virus activity of <italic>Ginkgo biloba</italic> leaf extracts.</article-title>
<source><italic>J. Nat. Med.</italic></source>
<volume>67</volume>
<fpage>636</fpage>&#x02013;<lpage>642</lpage>. <pub-id pub-id-type="doi">10.1007/s11418-012-0725-0</pub-id>
<?supplied-pmid 23179317?><pub-id pub-id-type="pmid">23179317</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>K.</given-names></name><name><surname>Hayashi</surname><given-names>T.</given-names></name><name><surname>Morita</surname><given-names>N.</given-names></name></person-group> (<year>1992</year>). <article-title>Mechanism of action of the antiherpesvirus biflavone ginkgetin.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>36</volume>
<fpage>1890</fpage>&#x02013;<lpage>1893</lpage>. <pub-id pub-id-type="doi">10.1128/aac.36.9.1890</pub-id>
<?supplied-pmid 1329635?><pub-id pub-id-type="pmid">1329635</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isah</surname><given-names>T.</given-names></name></person-group> (<year>2015</year>). <article-title>Rethinking <italic>Ginkgo biloba</italic> L. Medicinal uses and conservation.</article-title>
<source><italic>Pharmacogn. Rev.</italic></source>
<volume>9</volume>
<fpage>140</fpage>&#x02013;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.4103/0973-7847.162137</pub-id>
<?supplied-pmid 26392712?><pub-id pub-id-type="pmid">26392712</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itzhaki</surname><given-names>R. F.</given-names></name></person-group> (<year>2018</year>). <article-title>Corroboration of a major role for herpes simplex virus type 1 in Alzheimer&#x02019;s Disease.</article-title>
<source><italic>Front. Aging Neurosci.</italic></source>
<volume>19</volume>:<issue>324</issue>
<pub-id pub-id-type="doi">10.3389/fnagi.2018.00324</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itzhaki</surname><given-names>R. F.</given-names></name><name><surname>Tabet</surname><given-names>N.</given-names></name></person-group> (<year>2017</year>). <article-title>Herpes simplex encephalitis and Alzheimer&#x02019;s disease: Is there a link?</article-title>
<source><italic>J. Neurol. Sci.</italic></source>
<volume>380</volume>
<fpage>20</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.jns.2017.06.046</pub-id>
<?supplied-pmid 28870568?><pub-id pub-id-type="pmid">28870568</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>S. H.</given-names></name><name><surname>Prichard</surname><given-names>M. N.</given-names></name></person-group> (<year>2014</year>). <article-title>Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance.</article-title>
<source><italic>Curr. Opin. Virol.</italic></source>
<volume>8</volume>
<fpage>54</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2014.06.003</pub-id>
<?supplied-pmid 25036916?><pub-id pub-id-type="pmid">25036916</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandakumar</surname><given-names>S.</given-names></name><name><surname>Manju</surname><given-names>V.</given-names></name></person-group> (<year>2017</year>). <article-title>Pharmacological applications of isorhamnetin: a short review.</article-title>
<source><italic>Int. J. Trend Sci. Res. Dev.</italic></source>
<volume>1</volume>
<fpage>672</fpage>&#x02013;<lpage>678</lpage>. <pub-id pub-id-type="doi">10.31142/ijtsrd2202</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kressmann</surname><given-names>S.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>W. E.</given-names></name><name><surname>Blume</surname><given-names>H. H.</given-names></name></person-group> (<year>2002</year>). <article-title>Pharmaceutical quality of different <italic>Ginkgo biloba</italic></article-title>
<article-title>brands.</article-title>
<source><italic>J. Pharm. Pharmacol.</italic></source>
<volume>54</volume>
<fpage>661</fpage>&#x02013;<lpage>669</lpage>. <?supplied-pmid 12005361?></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S.</given-names></name><name><surname>Pandey</surname><given-names>A. K.</given-names></name></person-group> (<year>2013</year>). <article-title>Chemistry and biological activities of flavonoids: an overview.</article-title>
<source><italic>Sci. World J.</italic></source>
<volume>2013</volume>:<issue>162750</issue>. <pub-id pub-id-type="doi">10.1155/2013/162750</pub-id>
<?supplied-pmid 24470791?><pub-id pub-id-type="pmid">24470791</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J.-H.</given-names></name><name><surname>Park</surname><given-names>J.-S.</given-names></name><name><surname>Lee</surname><given-names>S.-W.</given-names></name><name><surname>Hwang</surname><given-names>S.-Y.</given-names></name><name><surname>Young</surname><given-names>B.-E.</given-names></name><name><surname>Choi</surname><given-names>H.-J.</given-names></name></person-group> (<year>2015</year>). <article-title>Porcine epidemic diarrhea virus infection: inhibition by polysaccharide from <italic>Ginkgo biloba</italic> exocarp and mode of its action.</article-title>
<source><italic>Virus Res.</italic></source>
<volume>195</volume>
<fpage>148</fpage>&#x02013;<lpage>152</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2014.09.013</pub-id>
<?supplied-pmid 25300802?><pub-id pub-id-type="pmid">25300802</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000fc;</surname><given-names>J.-M.</given-names></name><name><surname>Yan</surname><given-names>S.</given-names></name><name><surname>Jamaluddin</surname><given-names>S.</given-names></name><name><surname>Weakley</surname><given-names>S. M.</given-names></name><name><surname>Liang</surname><given-names>Z.</given-names></name><name><surname>Siwak</surname><given-names>E. B.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Ginkgolic acid inhibits HIV protease activity and HIV infection in vitro.</article-title>
<source><italic>Med. Sci. Monit. Int. Med. J. Exp. Clin. Res.</italic></source>
<volume>18</volume>
<fpage>BR293</fpage>&#x02013;<lpage>BR298</lpage>. <?supplied-pmid 22847190?><pub-id pub-id-type="pmid">22847190</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>Y. K.</given-names></name><name><surname>Adelung</surname><given-names>R.</given-names></name><name><surname>R&#x000f6;hl</surname><given-names>C.</given-names></name><name><surname>Shukla</surname><given-names>D.</given-names></name><name><surname>Spors</surname><given-names>F.</given-names></name><name><surname>Tiwari</surname><given-names>V.</given-names></name></person-group> (<year>2011</year>). <article-title>Virostatic potential of micro-nano filopodia-like ZnO structures against herpes simplex virus-1.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>92</volume>
<fpage>305</fpage>&#x02013;<lpage>312</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2011.08.017</pub-id>
<?supplied-pmid 21893101?><pub-id pub-id-type="pmid">21893101</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohanta</surname><given-names>T. K.</given-names></name><name><surname>Tamboli</surname><given-names>Y.</given-names></name><name><surname>Zubaidha</surname><given-names>P. K.</given-names></name></person-group> (<year>2014</year>). <article-title>Phytochemical and medicinal importance of <italic>Ginkgo biloba</italic> L.</article-title>
<source><italic>Nat. Prod. Res.</italic></source>
<volume>28</volume>
<fpage>746</fpage>&#x02013;<lpage>752</lpage>. <pub-id pub-id-type="doi">10.1080/14786419.2013.879303</pub-id>
<?supplied-pmid 24499319?><pub-id pub-id-type="pmid">24499319</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsania</surname><given-names>M.</given-names></name><name><surname>Rezaee</surname><given-names>M.-B.</given-names></name><name><surname>Monavari</surname><given-names>S. H.</given-names></name><name><surname>Jaimand</surname><given-names>K.</given-names></name><name><surname>Mousavi-Jazayeri</surname><given-names>S. M.</given-names></name><name><surname>Razazian</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Antiviral screening of four plant extracts against acyclovir resistant herpes simplex virus type-1.</article-title>
<source><italic>Pak. J. Pharm. Sci.</italic></source>
<volume>30</volume>
<fpage>1407</fpage>&#x02013;<lpage>1411</lpage>. <?supplied-pmid 29043989?><pub-id pub-id-type="pmid">29043989</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pritchett</surname><given-names>J. C.</given-names></name><name><surname>Naesens</surname><given-names>L.</given-names></name><name><surname>Montoya</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). &#x0201c;<article-title>Chapter 19 - treating hhv-6 infections: the laboratory efficacy and clinical use of Anti-HHV-6 agents</article-title>,&#x0201d; in <source><italic>Human Herpesviruses HHV-6A, HHV-6B &#x00026; HHV-7</italic></source>, <edition>3rd Edn</edition>, <role>eds</role>
<person-group person-group-type="editor"><name><surname>Flamand</surname><given-names>L.</given-names></name><name><surname>Lautenschlager</surname><given-names>I.</given-names></name><name><surname>Krueger</surname><given-names>G. R. F.</given-names></name><name><surname>Ablashi</surname><given-names>D. V.</given-names></name></person-group>, (<publisher-loc>Boston</publisher-loc>: <publisher-name>Elsevier</publisher-name>), <fpage>311</fpage>&#x02013;<lpage>331</lpage>. <pub-id pub-id-type="doi">10.1016/b978-0-444-62703-2.00019-7</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rechenchoski</surname><given-names>D. Z.</given-names></name><name><surname>Faccin-Galhardi</surname><given-names>L. C.</given-names></name><name><surname>Linhares</surname><given-names>R. E. C.</given-names></name><name><surname>Nozawa</surname><given-names>C.</given-names></name></person-group> (<year>2017</year>). <article-title>Herpesvirus: an underestimated virus.</article-title>
<source><italic>Folia Microbiol.</italic></source>
<volume>62</volume>
<fpage>151</fpage>&#x02013;<lpage>156</lpage>. <pub-id pub-id-type="doi">10.1007/s12223-016-0482-7</pub-id>
<?supplied-pmid 27858281?><pub-id pub-id-type="pmid">27858281</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnitzler</surname><given-names>P.</given-names></name><name><surname>Schuhmacher</surname><given-names>A.</given-names></name><name><surname>Astani</surname><given-names>A.</given-names></name><name><surname>Reichling</surname><given-names>J.</given-names></name></person-group> (<year>2008</year>). <article-title>Melissa officinalis oil affects infectivity of enveloped herpesviruses.</article-title>
<source><italic>Phytomed. Int. J. Phytother. Phytopharm.</italic></source>
<volume>15</volume>
<fpage>734</fpage>&#x02013;<lpage>740</lpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2008.04.018</pub-id>
<?supplied-pmid 18693101?><pub-id pub-id-type="pmid">18693101</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shlomo</surname><given-names>S.</given-names></name></person-group> (<year>2009</year>). <article-title>New effect size rules of thumb.</article-title>
<source><italic>J. Mod. Appl. Stat. Methods Vol.</italic></source>
<volume>8</volume>
<fpage>597</fpage>&#x02013;<lpage>599</lpage>. <pub-id pub-id-type="doi">10.22237/jmasm/1257035100</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>C.-J.</given-names></name><name><surname>Li</surname><given-names>C.-L.</given-names></name><name><surname>Tai</surname><given-names>C.-J.</given-names></name><name><surname>Wang</surname><given-names>C.-K.</given-names></name><name><surname>Lin</surname><given-names>L.-T.</given-names></name></person-group> (<year>2015</year>). <article-title>Early viral entry assays for the identification and evaluation of antiviral compounds.</article-title>
<source><italic>J. Vis. Exp.</italic></source>
<volume>29</volume>:<issue>e53124</issue>. <pub-id pub-id-type="doi">10.3791/53124</pub-id>
<?supplied-pmid 26555014?><pub-id pub-id-type="pmid">26555014</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyler</surname><given-names>K. L.</given-names></name></person-group> (<year>2004</year>). <article-title>Herpes simplex virus infections of the central nervous system: encephalitis and meningitis, including Mollaret&#x02019;s.</article-title>
<source><italic>Herpes J. IHMF</italic></source>
<volume>11(Suppl. 2)</volume>, <fpage>57A</fpage>&#x02013;<lpage>64A</lpage>.</mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ude</surname><given-names>C.</given-names></name><name><surname>Schubert-Zsilavecz</surname><given-names>M.</given-names></name><name><surname>Wurglics</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title><italic>Ginkgo biloba</italic> extracts: a review of the pharmacokinetics of the active ingredients.</article-title>
<source><italic>Clin. Pharmacokinet.</italic></source>
<volume>52</volume>
<fpage>727</fpage>&#x02013;<lpage>749</lpage>. <pub-id pub-id-type="doi">10.1007/s40262-013-0074-5</pub-id>
<?supplied-pmid 23703577?><pub-id pub-id-type="pmid">23703577</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.-Z.</given-names></name><name><surname>Li</surname><given-names>W.-J.</given-names></name><name><surname>Tao</surname><given-names>R.</given-names></name><name><surname>Ye</surname><given-names>J.-Z.</given-names></name><name><surname>Zhang</surname><given-names>H.-Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Antiviral activity of a nanoemulsion of polyprenols from ginkgo leaves against influenza A H3N2 and hepatitis B virus in vitro.</article-title>
<source><italic>Mol. Basel Switz.</italic></source>
<volume>20</volume>
<fpage>5137</fpage>&#x02013;<lpage>5151</lpage>. <pub-id pub-id-type="doi">10.3390/molecules20035137</pub-id>
<?supplied-pmid 25808155?><pub-id pub-id-type="pmid">25808155</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wigginton</surname><given-names>K. R.</given-names></name><name><surname>Pecson</surname><given-names>B. M.</given-names></name><name><surname>Sigstam</surname><given-names>T.</given-names></name><name><surname>Bosshard</surname><given-names>F.</given-names></name><name><surname>Kohn</surname><given-names>T.</given-names></name></person-group> (<year>2012</year>). <article-title>Virus inactivation mechanisms: impact of disinfectants on virus function and structural integrity.</article-title>
<source><italic>Environ. Sci. Technol.</italic></source>
<volume>46</volume>
<fpage>12069</fpage>&#x02013;<lpage>12078</lpage>. <pub-id pub-id-type="doi">10.1021/es3029473</pub-id>
<?supplied-pmid 23098102?><pub-id pub-id-type="pmid">23098102</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yarmolinsky</surname><given-names>L.</given-names></name><name><surname>Huleihel</surname><given-names>M.</given-names></name><name><surname>Zaccai</surname><given-names>M.</given-names></name><name><surname>Ben-Shabat</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Potent antiviral flavone glycosides from <italic>Ficus benjamina</italic> leaves.</article-title>
<source><italic>Fitoterapia</italic></source>
<volume>83</volume>
<fpage>362</fpage>&#x02013;<lpage>367</lpage>. <pub-id pub-id-type="doi">10.1016/j.fitote.2011.11.014</pub-id>
<?supplied-pmid 22155188?><pub-id pub-id-type="pmid">22155188</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuo</surname><given-names>W.</given-names></name><name><surname>Yan</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Mei</surname><given-names>D.</given-names></name></person-group> (<year>2017</year>). <article-title>Advances in the studies of <italic>Ginkgo biloba</italic></article-title>
<article-title>leaves extract on aging-related diseases.</article-title>
<source><italic>Aging Dis.</italic></source>
<volume>8</volume>
<fpage>812</fpage>&#x02013;<lpage>826</lpage>. <pub-id pub-id-type="doi">10.14336/AD.2017.0615</pub-id>
<?supplied-pmid 29344418?></mixed-citation></ref></ref-list><glossary><title>Abbreviations</title><def-list id="DL1"><def-item><term>CNS</term><def><p>central nervous system</p></def></def-item><def-item><term>CC<sub>50</sub></term><def><p>cytotoxic concentration</p></def></def-item><def-item><term>CI</term><def><p>confident interval</p></def></def-item><def-item><term>CPEs</term><def><p>cytopathic effects</p></def></def-item><def-item><term>CTEs</term><def><p>cytotoxic effects</p></def></def-item><def-item><term>DMEM</term><def><p>Dulbecco medium</p></def></def-item><def-item><term>DMSO</term><def><p>dimethyl sulfoxide</p></def></def-item><def-item><term>EGb</term><def><p>extract of <italic>Ginkgo biloba</italic></p></def></def-item><def-item><term>FBS</term><def><p>fetal bovine serum</p></def></def-item><def-item><term>HA</term><def><p>hemagglutinin</p></def></def-item><def-item><term>HHV-1</term><def><p>human alphaherpesvirus 1</p></def></def-item><def-item><term>HHV-2</term><def><p>human alphaherpesvirus 2</p></def></def-item><def-item><term>HIV</term><def><p><italic>human immunodeficiency virus</italic></p></def></def-item><def-item><term>IC<sub>50</sub></term><def><p>inhibitory concentration</p></def></def-item><def-item><term>NA</term><def><p>neuraminidase</p></def></def-item><def-item><term>PEDV</term><def><p><italic>porcine epidemic diarrhea virus</italic></p></def></def-item><def-item><term>SI</term><def><p>selectivity index</p></def></def-item><def-item><term>TCID<sub>50</sub></term><def><p>tissue culture infectious dose.</p></def></def-item></def-list></glossary></back></article>